



LUND UNIVERSITY
Faculty of Medicine

LUP

Lund University Publications
Institutional Repository of Lund University

This is an author produced version of a paper published in Molecular and cellular endocrinology. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:

Alexander Balhuizen, Rajesh Kumar, Stefan Amisten,
Ingmar Lundquist, S Albert Salehi

“Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice.”

Molecular and cellular endocrinology,
2010, Feb 1

<http://dx.doi.org/10.1016/j.mce.2010.01.030>

Access to the published version may
require journal subscription.

Published with permission from: Elsevier

1 **Research paper**

2
3 **Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts**
4 **cytokine-induced apoptosis in pancreatic islets of female mice**

5
6 **Alexander Balhuizen¹, Rajesh Kumar¹, Stefan Amisten¹, Ingmar Lundquist^{1,2} and Albert Salehi¹**

7 *Department of Clinical Science, Islet Cell Physiology¹ and Department of Experimental Medical*
8 *Science², University of Lund¹, Sweden*

9 *Running title: Islet GPR30 and hormone release*

10
11 *Address correspondence to: Dr. Albert Salehi, Department of Clinical Science, UMAS, Division of*
12 *Islet Cell Physiology, CRC, Building 91, Plan 11, Entrance 72, S-205 02 Malmö, Sweden; Tel: +46 40*
13 *391162; Fax: +46 40 391212; E-mail: S_Albert.Salehi@med.lu.se*

14
15
16
17 **Keywords: GPR30, Islet hormone secretion, cAMP, Apoptosis, G-1, 17 β -estradiol.**

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 *Address correspondence to:*

40 *Dr. Albert Salehi,*
41 *University of Lund,*
42 *Department of Clinical Science, UMAS,*
43 *Division of Islet Cell Physiology,*
44 *CRC, Building 91, Plan 11,*
45 *Entrance 72,*
46 *S-205 02 Malmö,*
47 *Sweden;*

48
49 *Tel: +46 40 391162;*
50 *Fax: +46 40 391212;*
51 *E-mail: S_Albert.Salehi@med.lu.se*

52

1 The role of the newly discovered estrogen receptor GPR30 in islet physiology and pathophysiology is
2 unclear. We examined GPR30 expression in relation to hormone secretion and possible anti-apoptotic
3 effects in isolated mouse islets using the synthetic GPR30 ligand G-1. The mRNA and protein
4 expression of GPR30 was analyzed by qPCR, Western blot and confocal microscopy. Hormone
5 secretion and cAMP content were determined with RIA and apoptosis in islet cells with the Annexin-
6 V method.

7 GPR30 mRNA and protein expression was markedly higher in islets from females compared to
8 male. This gender difference was not found for the genomic estrogen receptors ER α and ER β , the ER α
9 expression being 10-fold higher than ER β in both genders. Confocal microscopy revealed abundant
10 GPR30 expression in insulin, glucagon and somatostatin cells. Dose-response studies of G-1 vs 17 β -
11 estradiol in isolated islets at 1 or 12 mM glucose showed an almost identical pattern in that both
12 compounds increased insulin and inhibited glucagon and somatostatin secretion. ICI-182,780 and EM-
13 652, potent antagonists of the 17 β -estradiol receptors (ER α and ER β) did not influence the amplifying
14 effect of G-1 or 17 β -estradiol on cAMP content or insulin secretion from isolated islets. Cytokine-
15 induced (IL-1 β + TNF α + INF γ) apoptosis in islets, cultured for 24 h at 5 mM glucose, was almost
16 abolished by G-1 or 17 β -estradiol treatment. Addition of ICI-182,780 or EM-652 did not affect this
17 beneficial effect of G-1 or 17 β -estradiol.

18 Taken together, our findings show that GPR30 is expressed in most islet endocrine cells. The
19 synthetic GPR30 ligand G-1 mimics the nongenomic effects of 17 β -estradiol on islet hormone
20 secretion, cAMP content in islets and its anti-apoptotic effects. G-1 or analogs thereof might be new
21 potential candidates in the therapeutic strategy for type 2 diabetes in women.

22

1. Introduction

Previous studies have shown that women display not only increased insulin sensitivity, and a better glucose tolerance but also a better insulin secretory response to nutrients compared to men, (Boyns et al.,1969; Yki-Järvinen,1984) and are more resistant to nutrition-induced insulin resistance (Frias et al.,2001; Hevener et al.,2002; Soeters et al.,2007). Likewise, female mice are less prone to diet induced insulin resistance (Corsetti et al.,2000; Zierath et al.,1997) and many genetically induced forms of insulin resistance have milder phenotypes in female compared with male mice (Corsetti et al.,2000; Li et al.,2000).

Genomic effects of estrogens through the nuclear estrogen receptors (ER) ER α and ER β have been recognized for a long time in several tissues including the islets of Langerhans (Prossnitz et al.,2007).

Recently, however, several reports have described rapid effects by 17 β -estradiol elicited through a non-classical membrane receptor, which has been shown to share the characteristics of a G protein-coupled receptor (GPCR). This receptor has been labeled GPR30 (Filardo et al.,2007; Martensson et al.,2009; Prossnitz et al.,2007).Very recently it was shown that deletion of GPR30 in female mice resulted in impaired glucose tolerance, reduced bone growth and increased vascular resistance (Martensson et al.,2009). Moreover, in that study we could show that glucose-stimulated insulin release was greatly impaired in GPR30^(-/-) mice both *in vitro* and *in vivo* (Martensson et al.,2009). In addition, the estrogen-induced suppression of glucagon secretion was almost abolished in GPR30^(-/-) mice (Martensson et al.,2009). Recent results from different studies suggest that 17 β -estradiol protects insulin secretory processes in various diabetic states and that the prevalence of diabetes is known to be lower in females than in males (Wild et al.,2004). Hence, we found it of interest to study whether GPR30 was expressed in the different pancreatic endocrine cells and if GPR30 activation could influence insulin, glucagon and somatostatin secretion as well as islet cell survival. To this end we used a non-steroidal, high affinity, selective agonist of GPR30 referred to as G-1 (GPR30-specific compound 1; a substituted dihydroquinoline) (Prossnitz et al.,2008). For comparative purposes, we also studied the influence of 17 β -estradiol.

2. Experimental procedures

2.1. Materials

Female and male mice of the NMRI strain (B&K, Sollentuna, Sweden) weighing 25-30g were used for the experiments. They were given a standard pellet diet (B&K) and tap water *ad libitum*. All animals were housed in metabolic cages with constant temperature (22°C) and 12-h light/dark cycles. The local animal welfare committee, (Lund, Sweden) approved the experimental protocols and all procedures using animals.

1 Collagenase (CLS 4) was from Sigma St. Louis, MO, USA. Fatty acid free bovine serum albumin
2 (BSA) was from Boehringer Mannheim, Germany. G-1 (1-[4-6-benzo [1, 3] dioxol-5-yl)-3a, 4, 5, 9b-
3 tetrahydro-3H-cyclopenta[c]quinoline-8-yl]-ethanone) and ICI 182,780 (Fulvestrant) were purchased
4 from Cayman, CA, USA. EM-652 ((2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-
5 ylethoxy)phenyl]-2H-chromen-7-ol) was kindly provided by Professor. F. Labrie, University
6 of Quebec, Canada. All other chemicals were from Merck AG, (Darmstadt, Germany) or Sigma
7 (USA).

8 9 *2.2. Isolation of pancreatic islets and islet hormone secretion measurements*

10 Preparation of mouse pancreatic islets was performed by clamping the distal end of the pancreatic duct
11 followed by a retrograde injection of ice-cold collagenase solution *via* the bile pancreatic duct. (Gotoh
12 et al.,1985) Thereafter pancreas was dissected out and placed in tubes and incubated at 37°C for 17
13 min. The pancreatic islets were then separated from acinar tissue by vigorous shaking in ice-cold
14 Hanks' solution for 3 minutes. Next the isolated islets were handpicked under a stereomicroscope at
15 room temperature. The isolated islets were then subjected to different experimental procedures (see
16 below).

17 The freshly isolated islets were pre-incubated for 30 min at 37°C in Krebs-Ringer bicarbonate
18 buffer, pH 7.4, supplemented with 10 mM HEPES, 0.1 % bovine serum albumin and 1.0 mM glucose.
19 After pre-incubation the buffer was changed and the islets were incubated with different
20 concentrations of test agents for 60 min at 37°C unless otherwise stated. Each incubation vial
21 contained 12 islets in 1.0 ml of buffer solution and was gassed with 95% O₂-5% CO₂ to obtain
22 constant pH and oxygenation. All incubations were performed in an incubation box at 30 cycles/min.
23 Immediately after incubation an aliquot of the medium was removed and frozen for subsequent assay
24 of the hormones by using commercial available radioimmunoassay kits following the manufacturer's
25 recommendations for insulin (Millipore, USA), glucagon and somatostatin (Diagnostika, Falkenberg,
26 Sweden) (Ahrén,1982; Heding,1966; Panagiotidis et al.,1992). The inter- and intra-assay coefficients
27 of variation were; for insulin 4.2 and 3.2 %; glucagon 8.3 and 6.8 % and somatostatin 3.2 and 6.1 %.
28 MIN64c cells (kindly donated by Professor J. Miyazaki, Osaka University Medical School) were
29 grown in Dulbecco's modified Eagle's medium (DMEM) with Glutamax-1 supplemented with 15 %
30 heat-inactivated FBS (Invitrogen, Paisley, UK), 60 µM β-mercaptoethanol, 50 U/ml penicillin and
31 50 µg/ml streptomycin. After acquiring ~95% confluent growth, the cells (~2 x 10⁶) were harvested
32 and used for qPCR and Western blot analysis.

33 34 *2.3. cAMP measurement*

35 For the measurement of cAMP, the female islets were first preincubated for 30 min at 1 mM glucose
36 (see above) and then incubated for 30 min at 37°C with 12 mM glucose in the absence or presence of

1 different test agents, 17 β -estradiol (100 nM or 5 μ M), G-1 (100nM), ICI 182,780 (100nM) and EM-
2 652 (100nM). Each incubation vial contained 40 islets in 1.5 ml of KRB-buffer. After the incubation
3 the islets were treated with 100 mM HCl for 5 min and then frozen. At the day of analysis samples
4 were sonicated on ice and cAMP was measured using a cAMP EIA kit (Cayman Chemical, USA)
5 according to manufacturer's instructions. The protein level was analyzed by the Bradford method
6 (Bradford,1976).

7 8 *2.4. Detection of mRNA for GPR30 by quantitative real-time PCR*

9 RNA from islets and MIN6c4 cells ($\sim 2 \times 10^6$) was isolated using TRIzol (Invitrogen) according to a
10 modified RNA extraction protocol and transcribed into cDNA as described elsewhere (Amisten et
11 al.,2008). qPCR was performed on a HT7900 system (Applied Biosystems) using QuantiTect primer
12 assays and QuantiFast SYBR Green PCR (all from Qiagen) according to the manufacturer's
13 instructions. The specificity of all primer assays was validated by melting curve analysis and gel
14 electrophoresis. Gene expression relative to GAPDH was calculated using the DDCT method
15 (Pfaffl,2001).

16 17 *2.5. Western blot*

18 Approximately 400 islets or MIN6c4 ($\sim 2 \times 10^6$) per vial (n=5 in each group) were suspended in 100 μ l
19 of SDS-buffer (50mM Tris-HCl, 1mM EDTA) containing a cocktail of protease inhibitors, frozen and
20 sonicated on ice on the day of analysis (Jimenez-Feltstrom et al.,2004).The protein content of the
21 homogenates was determined according to the Bradford method (Bradford,1976). Homogenate
22 samples representing 20 μ g of total protein were run on 7,5% SDS-polyacrylamide gel (Bio-Rad,
23 Hercules, CA, USA). After electrophoresis, proteins were transferred to a nitrocellulose membrane
24 (Bio-Rad, Hercules, CA, USA). The membrane was blocked in LS-buffer (10 mM Tris, pH 7.4, 100
25 mM NaCl, 0.1% Tween-20) containing 5% non-fat dry milk powder for 40 min at 37°C. Subsequently
26 the membranes were incubated over night with a rabbit-raised polyclonal anti-GPR30 antibody
27 (Acromed Invest, Sweden) against the C-terminal peptide: NH₂-AVIPDSTEQSEVRFSSAV-COOH
28 (1:150) at room temperature. The specificity of the antibody was evaluated in islets from GPR30^(-/-)
29 mice (data not shown). After washing (three times) in LS-buffer the membrane was finally incubated
30 with a horseradish peroxidase-conjugated anti-rabbit antibody (1:500). Immunoreactivity was detected
31 using an enhanced chemiluminescence reaction (Pierce, Rockford, IL, USA). For detection of β -actin
32 as endogenous control a commercially available antibody was used (BioGenesis, UK)

33 34 *2.6. Confocal microscopy*

35 The freshly isolated female mouse islets were washed with PBS and fixed with 4% formaldehyde,
36 permeabilized with 5% Triton X-100, and unspecific sites were blocked with 5% Normal Donkey
37 Serum (Jackson Immunoresearch Laboratories Inc, West Grove, PA). GPR30 was detected with the

1 same antibody as used for Western blot (1:50). For staining of insulin, glucagon and somatostatin we
2 used the following antibodies, guinea pig anti-insulin (Eurodiagnostica, Malmö, Sweden) (1:500),
3 guinea pig anti-glucagon (1:500) and rat anti-somatostatin (1:250) both from Jackson Immunoresearch
4 Laboratories, followed by treatment with fluorescent-conjugated secondary antibodies (1:50-75) from
5 Jackson Immunoresearch Laboratories. The fluorescence was visualized with a Zeiss LSM510
6 confocal microscope by sequentially scanning at (excitation/emission) 488/505-530 nm (Cy2),
7 543/570(Cy3) and 633/>650 nm (Cy5).

9 2.7. Apoptosis measurement

10 Islets isolated from female mice were dispersed into single cells using Ca^{2+} free-medium. The cells
11 were incubated with and without a cocktail of cytokines *i.e.* IL-1 β (100 ng/ml), TNF α (125 ng/ml),
12 and INF γ (125 ng/ml). The effects of 17 β -estradiol (100 nM or 5 μM) or G-1(100 nM) on the
13 cytokine-induced apoptosis were studied in the absence or presence of ICI 182,780 (100 nM) or EM-
14 652 (100 nM) after 24 h culture of the cells in RPMI1640 medium with 5 mM glucose and 10% FSB.
15 The detection of apoptosis was performed on a FACS-system with the Annexin V-staining method
16 (BDPharmigen, USA) according to manufacturer's instructions, and the flow cytometry data was
17 analysed using the FlowJo and CellQuest software packages.

19 2.8. Statistics

20 All results are expressed as means \pm SEM for the indicated number of observations or illustrated by an
21 observation representative for a number of different experiments (Western blots, confocal
22 microscopy). Probability levels of random differences were determined by analysis of variance
23 followed by Tukey-Kramers' multiple comparisons test. The EC50 values (Fig. 3) were calculated
24 from a non-linear sigmoid curve fit using GraphPad Prism 4. A P- value of <0.05 was considered
25 significant (*P < 0.05; ** < 0.01; ***P < 0.001).

27 3. Results

29 3.1. mRNA and protein expression of GPR30 in female and male mice islets

30 Control experiments showed no differences between female and male mice islets with regard to
31 mRNA expression for ER α and ER β (Figure 1A). Notably ER α expression was almost 10-fold higher
32 than ER β (p<0.01) in both female and male mice islets (Figure 1A). However, the expression of
33 GPR30 mRNA relative to house keeping gene GAPDH was found to be higher in female [(9.5 \pm 1.0) x
34 10⁻³] compared to male mice islets [(5.5 \pm 0.7 x 10⁻³)] (p<0.01; n=10 in each group) (Figure 1A). The
35 mRNA expression of GPR30 in the β -cell line MIN6c4 was comparatively much lower (n=10)
36 (p<0.001) (Figure 1A).

1 Densitometric analysis of Western blots revealed that also on the protein level, GPR30 was more
2 abundant in islet homogenates from female (0.20 ± 0.027 relative intensity of GPR30/ β -actin)
3 compared to male (0.13 ± 0.018 relative intensity GPR30/ β -actin) mice ($p < 0.05$). The quantified
4 protein level of GPR30 in MIN6c4 cells (0.012 ± 0.016 relative intensity GPR30/ β -actin) was
5 markedly lower compared to islets from both female and male mice ($p < 0.001$) ($n = 5$ in each group)
6 (Figure 1B - C).

7 8 *3.2. GPR30 expression in different islet cell types*

9 In order to investigate the cell-specific expression of GPR30, isolated islets from female mice were
10 simultaneously immunolabelled for either insulin, glucagon or somatostatin together with GPR30 and
11 analyzed by confocal microscopy. As seen in Figure 2A-I, GPR30 could be visualized in the different
12 islet cell types and showed a strong co-localization with insulin (2A-C), (89 ± 3.2 % of the insulin
13 positive cells, $n = 8$), glucagon (2D-F), (82 ± 1.1 % of the glucagon positive cells, $n = 8$) and
14 somatostatin (2G-I) (87 ± 0.7 % of the somatostatin positive cells, $n = 8$) could be observed in all
15 investigated islets.

16 17 *3.3. Effect of GPR30 activation on islet hormone release*

18 Next experiment we compared the effects of G-1, a specific GPR30 agonist, (Bologa et al., 2006) and
19 17β -estradiol on islet hormone secretion at both low (1 mM) (Figure 3A, C and E) and high (12 mM)
20 (Figure 3B, D and F) glucose concentrations (Figure 3A-F). Neither 17β -estradiol nor G-1 had any
21 significant effect on insulin release from isolated female islets at basal glucose (1 mM) under static
22 incubation conditions (1 h) (Figure 3A) whereas both agents dose-dependently potentiated insulin
23 secretion in the presence of 12 mM glucose (Figure 3B). The potentiating effect of 17β -estradiol was
24 almost one order of magnitude higher compared to the effects of G-1 on insulin secretion at 12 mM
25 glucose. The calculated EC₅₀ values for the modulatory action of 17β -estradiol and G-1 on insulin
26 release were 1.88×10^{-8} (17β -estradiol) and 1.22×10^{-7} (G-1). In contrast, glucagon secretion at 1 mM
27 glucose was dose-dependently inhibited by both 17β -estradiol and G-1 in a similar way (Figure 3C).
28 The calculated EC₅₀ values for the inhibitory action of 17β -estradiol (8.79×10^{-11}) and G-1 (9.58×10^{-11})
29 on glucagon release were of the same magnitude. The suppressive effect of high glucose (12 mM)
30 on glucagon release, however, was not further modulated by G-1 (Figure 3D). Somatostatin release at
31 basal glucose (1 mM) was not notably affected by 17β -estradiol or G-1 whereas somatostatin secretion
32 at 12 mM glucose was dose-dependently inhibited by both 17β -estradiol and G-1 (Figure 3D and E).
33 The calculated EC₅₀ values for the suppressive effects of 17β -estradiol (1.93×10^{-9}) and G-1 ($5.79 \times$
34 10^{-9}) on somatostatin secretion were of similar magnitude.

35 36 37 *3.4. Effect of GPR30 activation on cAMP generation in relation to insulin release*

1 To further study the rapid effect of GPR30 activation by 17 β -estradiol or G-1 we incubated isolated
2 islets for 30 min and measured islet content of cAMP as well as insulin release in the presence and
3 absence of the nuclear estrogen receptor antagonists ICI 182,780 or EM-652. Figure 4 shows that, in
4 the presence of 12 mM glucose, 17 β -estradiol as well as G-1 strongly stimulated cAMP generation in
5 parallel with insulin release both in the absence ($p < 0.001$) and presence ($p < 0.001$) of ICI 182,780 and
6 EM-652. Regarding 17 β -estradiol, a more pronounced effect was observed at 5 μ M compared to a
7 lower concentration of 17 β -estradiol (100 nM) (Figure 4).

9 *3.5. Effect of 17 β -estradiol or G-1 on cytokine-induced apoptosis in islet cells in the absence and* 10 *presence of ICI 182,780 or EM-652*

11 Dispersed female islet cells were cultured for 24 h in 5 mM glucose with and without a mixture of
12 cytokines (IL-1 β , TNF α and INF γ) (Figure 5A). Addition of 17 β -estradiol or G-1 to the culture
13 medium almost abolished the cytokine-induced apoptosis (Figure 5B-C). The estrogen nuclear
14 receptor antagonists ICI 182, 780 and EM-652 did not influence the cytokine-induced apoptosis
15 (Figure 6A). The potent antagonist EM-652 did not influence the anti-apoptotic effects of either 17 β -
16 estradiol (100 nM or 5 μ M) or G-1 (100 nM) (Figure 6B-C). Figure 7 illustrates quantitatively the sum
17 of the anti-apoptotic effect of both 17 β -estradiol and G-1, as shown in figure 5 and 6, from 8 different
18 observations performed at 5 different occasions ($p < 0.001$). As shown, the protective effect against
19 apoptosis was clearly evident also in the presence of either ICI 182,780 or EM-652 (Figure 7).

21 **4. Discussion**

23 It has been described recently that the putative membrane-associated estrogen receptors either are
24 intimately linked to or distinct from the classical nuclear receptors (Filardo et al.,2007; Filardo et
25 al.,2002; Filippo Acconcia,2003; Govind and Thampan,2003). Although still controversial, current
26 studies point at the involvement of a G protein-coupled receptor for non-genomic, rapid effects of
27 estrogen in different tissues including excitable cells such as neurons and endocrine cells (Filardo et
28 al.,2007; Martensson et al.,2009; Prossnitz et al.,2007; Prossnitz et al.,2008; Qiu et al.,2008)

29 The present study was focused on the expression and function of GPR30 in endocrine pancreas.
30 While islet mRNA expression for ER α and ER β did not differ between genders, ER α being markedly
31 higher than ER β in both female and male mice islets, we demonstrated here that GPR30 mRNA and
32 protein expression was much higher in isolated islets from female than male mice and very low in the
33 β -cell line MIN6c4. Importantly, MIN6c4 cells should be considered less suitable for GPR30
34 screening and functional studies. Further, we found that GPR30 protein expression, as visualized by
35 confocal microscopy, was abundant in insulin, glucagon and somatostatin cells comprising 82-89 % of
36 the different cell types. Moreover, functional studies on isolated islets in short-time incubations
37 showed that the GPR30 specific ligand G-1 stimulated insulin release and inhibited glucagon and

1 somatostatin release in a manner almost identical to 17 β -estradiol. Incubation of isolated islets at 12
2 mM glucose in the presence of either G-1 or 17 β -estradiol induced an increase of cAMP content in
3 parallel with an amplified insulin release. These effects were neither influenced by ICI 182,780 a
4 blocker of the classical estrogen receptors ER α and ER β nor by EM-652 which has a most potent
5 inhibitory activity on both ER α and ER β compared to other anti-estrogens tested. (Labrie et al.,1999).

6 In order to assess a potential independent role of GPR30; we have used the new antagonist EM-652
7 which has no agonistic effect on GPR30. This is in contrast to ICI 182,780 which in previous studies
8 has been shown to be a nuclear receptor blocker as well as having partial agonistic properties on
9 GPR30 in other tissues (Rae and Johnson,2005; Smith et al.,2009). Apparently ICI 182,780 might be
10 tissue specific with regard to its agonistic activity, since we could not find any agonistic effect on
11 GPR30 in female mice islets.

12 Altogether, the present data speak in favour of GPR30 being an important receptor for rapid
13 estrogen effects. In the present work we also demonstrate for the first time that the long-term anti-
14 apoptotic effects of 17 β -estradiol can be mediated via activation of GPR30 in the presence of the ER α
15 and ER β antagonists ICI 182,780 and EM-652 after culturing islets for 24 hours with a mixture of
16 cytokines.

17 It has previously been shown that 17 β -estradiol exerts a rapid insulinotropic effect through
18 activating of a plasma membrane receptor (Nadal et al.,1998). The authors showed that 17 β -estradiol,
19 in synergy with glucose, depolarized the β -cell membrane and elicited electrical activity and [Ca²⁺]_i
20 signals to promote insulin release. By specific competitive binding studies they concluded that a novel
21 17 β -estradiol receptor was localized at the plasma membrane and was responsible for K_{ATP} channel
22 regulation and Ca²⁺ signals. Later on the same group reported that also the glucagon producing α -cells
23 were provided with non-classical estrogen receptors at the plasma membrane and that activation of
24 these receptors prevented the low-glucose-induced [Ca²⁺]_i oscillations in these cells (Ropero et
25 al.,2002). Furthermore, competition studies with 17 β -estradiol-linked horseradish peroxidase
26 suggested that this estrogen receptor at the plasma membrane was neither ER α nor ER β (Ropero et
27 al.,2002). The results of the present investigation are in accordance with these earlier data and strongly
28 suggest that this estrogen receptor is identical to the G protein-coupled receptor 30 (GPR30), recently
29 described in other tissues (Prossnitz et al.,2007) and we very recently found that deletion of GPR30
30 (GPR30^{-/-}) in female mice resulted in a marked impairment of glucose stimulated insulin release both
31 *in vivo* and from *in vitro* isolated islets (Martensson et al.,2009). Moreover, estrogen-stimulated
32 insulin release from islets of GPR30^{-/-} mice was abolished although serum estrogen levels were
33 apparently normal in these mice (Martensson et al.,2009). We could now show that GPR30 is
34 expressed not only in the insulin-producing β -cells and the glucagon-producing α -cells but also in the
35 somatostatin-producing δ -cells. The functional studies presented here using the newly developed
36 GPR30-specific agonist G-1 lend further support to GPR30 being an important plasma membrane-

1 associated estrogen receptor in that short-time incubation of isolated islets in the presence of a wide
2 range of G-1 concentrations showed a dose-response pattern of hormone release similar to 17 β -
3 estradiol i.e. a gradual increase of insulin secretion and a gradual suppression of glucagon and
4 somatostatin secretion. This modulatory effect of GPR30 on insulin and glucagon secretion is
5 apparently dependent on ambient glucose levels. As seen in Figure 3 there is no effect on insulin
6 secretion at low glucose, while glucagon secretion is suppressed. At 12 mM glucose, however, GPR30
7 stimulation amplifies insulin release and suppresses somatostatin release thus manifesting an anti-
8 diabetic action. The potentiating effect of 17 β -estradiol was almost one order of magnitude higher
9 compared to G-1 on glucose-stimulated insulin secretion while no difference was found with regard to
10 the effect on glucagon and somatostatin secretion. Although not directly tested in the present study it
11 seems not inconceivable that 17 β -estradiol, has a greater efficacy at GPR30 than the synthetic
12 compound, G-1 and/or 17 β -estradiol might exert another short-time action independent of GPR30
13 (Kelly and Ronnekleiv,2009). Moreover, although ligand receptor-binding studies have suggested that
14 G-1 compared to 17 β -estradiol has stronger affinity for GPR30 (Prossnitz et al.,2008; Prossnitz and
15 Maggiolini,2009; Prossnitz and Maggiolini,2009; Prossnitz et al.,2008) our data show that 17 β -
16 estradiol is more potent than G-1 to stimulate insulin release. This is in good agreement with previous
17 dose-response studies showing that affinity and efficacy are separate quantities *i.e.* pharmacological
18 response to a drug with a lower receptor-affinity could comparatively be of the same magnitude or
19 even higher (Colquhoun,1998; Williams and Sewing,2005). Furthermore, a certain effect with regard
20 to glucagon secretion cannot be excluded, since 17 β -estradiol action on the glucagon cells is obviously
21 exerted at lower concentrations compared to the 17 β -estradiol effect on insulin release. This might be
22 due to a higher receptor density on the glucagon cells.

23 The lack of amplifying effects by 17 β -estradiol or G-1 on insulin release at low glucose
24 concentration could be explained by the fact that low glucose levels are not capable of
25 elevating/generating intracellular signals such as Ca²⁺ and cAMP that are important for insulin and
26 somatostatin secretion. Regarding the absence of suppressive effects of 17 β -estradiol or G-1 on
27 glucagon release at high glucose level, it should be mentioned that an intermediate high glucose
28 concentration (12 mM), as previously shown, is a potent suppressor of glucagon release (Vieira et
29 al.,2007). The suppressive effects of 17 β -estradiol or G-1 on glucagon secretion could, however, be
30 masked by the presence of a high glucose concentration in the incubation media (Figure 3D). Hence,
31 these dose-dependent effects of G-1, a GPR30 specific ligand, which mimics the 17 β -estradiol effect
32 on pancreatic hormone release further support GPR30 being an important plasma membrane-
33 associated estrogen receptor. These cumulative data highlight a positive anti-diabetic role of GPR30
34 agonists such as G-1 on islet hormone secretion.

35 There has been extensive work done in other tissues which showed that 17 β -estradiol increases
36 cAMP levels as a result of its ability to stimulate adenylate cyclase (Aronica et al.,1994; Nakhla et
37 al.,1990). These findings together with the observation that 17 β -estradiol stimulates Ca²⁺ (Morley et

1 al.,1992), inositol trisphosphate (Le Mellay et al.,1997) and heterotrimeric G proteins (Le Mellay et
2 al.,1999) led these investigators to speculate that GPCRs might be implicated in rapid estrogen
3 signalling. Moreover, estrogen-stimulated insulin release from islets of GPR30^(-/-) mice was abolished
4 although serum estrogen levels were apparently normal in GPR30^(-/-) mice (Martensson et al.,2009).
5 However, the intracellular signalling following G-1 activation of GPR30 in the different islet cells is
6 far from elucidated. As previously mentioned, 17 β -estradiol triggers opposite [Ca²⁺]_i responses in β -
7 and α -cells (Ropero et al.,2008) which would lead to increased insulin and decreased glucagon
8 secretion. In the present study we found that, in the presence of glucose, G-1 as well as 17 β -estradiol
9 stimulated the generation of cAMP content in parallel with increased insulin release. These data
10 further support that cAMP plays an important role in Ca²⁺-induced exocytosis of insulin (Eliasson et
11 al.,2003) and that the adenylate cyclase-cAMP system is stimulated through activation of GPR30 in
12 other tissues (Prossnitz et al.,2007). Neither cAMP generation nor insulin release was affected by the
13 presence of ICI 182,780 and EM-652, showing that the classical estrogen receptors ER α and ER β were
14 not involved.

15 Finally we found for the first time that also long-term effects by G-1 and 17 β -estradiol could be
16 exerted through GPR30 activation in that cytokine-induced apoptosis in islets cultured for 24 h was
17 almost abolished by these estrogen compounds, with and without the presence of ICI 182,780 or EM-
18 652. A functional failure of insulin producing pancreatic β -cells is a common characteristic of type 1
19 (insulin-dependent) and type 2 (non insulin-dependent) diabetes mellitus. Accumulating evidence
20 suggests that programmed cell death (apoptosis) is a main form of β -cell death in these disorders
21 (Mandrup-Poulsen,2003). It has been reported in previous studies that 17 β -estradiol prevents β -cell
22 apoptosis in the absence of ER α (Le May et al.,2006). One possibility to explain this finding is that
23 17 β -estradiol may activate a non-genomic pathway *via* membrane GPR30 receptors unrelated to ERs
24 and thus prevent β -cell apoptosis. Therefore we tested whether 17 β -estradiol and G-1, a selective
25 agonist of GPR30, could protect pancreatic islets from cytokine-induced apoptosis when the nuclear
26 ER α and ER β were not functional. The results were quite striking in that G-1 or 17 β -estradiol
27 markedly reduced the level of apoptosis induced by a mixture of IL-1 β , TNF α and INF γ in the
28 presence of the nuclear ER receptor antagonists ICI 182,780 and EM-652. Our data thus clearly
29 indicate that GPR30 plays a main role in mediating the beneficial effects of estrogen in preventing the
30 cytokine induced pancreatic β -cell apoptosis.

31 In conclusion, our present findings suggest that drugs targeting GPR30 specifically might be a new
32 therapeutic option in the management of type 2 diabetes, not only by potentiating insulin secretion and
33 inhibiting glucagon and somatostatin secretion but also by suppressing inflammatory injuries induced
34 by cytokines on pancreatic islets. Indeed successful treatment of type 2 diabetes has been achieved by
35 using IL-1 β antagonists (Maedler and Donath,2004) suggesting an inflammatory component in the
36 pathogenesis of type 2 diabetes.

37

- 1 Ahrén, B., Lundquist, I 1982. Glucagon immunoreactivity in plasma from normal and dystrophic
2 mice. *Diabetologia* 4, 258-63.
- 3 Amisten, S., Braun, O.O., Bengtsson, A. and Erlinge, D. 2008. Gene expression profiling for the
4 identification of G-protein coupled receptors in human platelets. *Thromb Res* 122, 47-57.
- 5 Aronica, S.M., Kraus, W.L. and Katzenellenbogen, B.S. 1994. Estrogen action via the cAMP signaling
6 pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. *Proc Natl*
7 *Acad Sci U S A* 91, 8517-21.
- 8 Bologa, C.G., Revankar, C.M., Young, S.M., Edwards, B.S., Arterburn, J.B., Kiselyov, A.S., Parker,
9 M.A., Tkachenko, S.E., Savchuck, N.P., Sklar, L.A., Oprea, T.I. and Prossnitz, E.R. 2006.
10 Virtual and biomolecular screening converge on a selective agonist for GPR30. *Nat Chem*
11 *Biol* 2, 207-212.
- 12 Boyns, D.R., Crossley, J.N., Abrams, M.E., Jarrett, R.J. and Keen, H. 1969. Oral glucose tolerance
13 and related factors in a normal population sample. I. Blood sugar, plasma insulin, glyceride,
14 and cholesterol measurements and the effects of age and sex. *Br Med J* 1, 595-8.
- 15 Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of
16 protein utilizing the principle of protein-dye binding. *Anal Biochem* 72, 248-54.
- 17 Colquhoun, D. 1998. Binding, gating, affinity and efficacy: the interpretation of structure-activity
18 relationships for agonists and of the effects of mutating receptors. *Br J Pharmacol* 125, 924-
19 47.
- 20 Corsetti, J.P., Sparks, J.D., Peterson, R.G., Smith, R.L. and Sparks, C.E. 2000. Effect of dietary fat on
21 the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty
22 male and female rats. *Atherosclerosis* 148, 231-241.
- 23 Eliasson, L., Ma, X., Renstrom, E., Barg, S., Berggren, P.-O., Galvanovskis, J., Gromada, J., Jing, X.,
24 Lundquist, I., Salehi, A., Sewing, S. and Rorsman, P. 2003. SUR1 Regulates PKA-
25 independent cAMP-induced Granule Priming in Mouse Pancreatic B-cells. *J. Gen. Physiol.*
26 121, 181-197.
- 27 Filardo, E., Quinn, J., Pang, Y., Graeber, C., Shaw, S., Dong, J. and Thomas, P. 2007. Activation of the
28 Novel Estrogen Receptor G Protein-Coupled Receptor 30 (GPR30) at the Plasma
29 Membrane. *Endocrinology* 148, 3236-3245.
- 30 Filardo, E.J., Quinn, J.A., Frackelton, A.R., Jr. and Bland, K.I. 2002. Estrogen action via the G
31 protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated
32 attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. *Mol Endocrinol*
33 16, 70-84.
- 34 Filippo Acconcia, M.M. 2003. Synergism between Genomic and Non Genomic Estrogen Action
35 Mechanisms. *IUBMB Life* 55, 145-150.
- 36 Frias, J.P., Macaraeg, G.B., Ofrecio, J., Yu, J.G., Olefsky, J.M. and Kruszynska, Y.T. 2001. Decreased
37 Susceptibility to Fatty Acid-Induced Peripheral Tissue Insulin Resistance in Women.
38 *Diabetes* 50, 1344-1350.
- 39 Gotoh, M., Maki, T., Kiyozumi, T., Satomi, S. and Monaco, A.P. 1985. An improved method for
40 isolation of mouse pancreatic islets. *Transplantation* 40, 437-8.
- 41 Govind, A.P. and Thampan, R.V. 2003. Membrane associated estrogen receptors and related proteins:
42 localization at the plasma membrane and the endoplasmic reticulum. *Mol Cell Biochem* 253,
43 233-40.
- 44 Heding, L. 1966. A simplified insulin radioimmunoassay method. (Labelled proteins in tracer studies.,
45 Euratom, Brussels.
- 46 Hevener, A., Reichart, D., Janez, A. and Olefsky, J. 2002. Female Rats Do Not Exhibit Free Fatty
47 Acid-Induced Insulin Resistance. *Diabetes* 51, 1907-1912.
- 48 Jimenez-Feltstrom, J., Lundquist, I., Obermuller, S. and Salehi, A. 2004. Insulin feedback actions:
49 complex effects involving isoforms of islet nitric oxide synthase. *Regul Pept* 122, 109-18.
- 50 Kelly, M.J. and Ronnekleiv, O.K. 2009. Control of CNS neuronal excitability by estrogens via
51 membrane-initiated signaling. *Molecular and Cellular Endocrinology* 308, 17-25.
- 52 Labrie, F., Labrie, C., Belanger, A., Simard, J., Gauthier, S., Luu-The, V., Merand, Y., Giguere, V.,
53 Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V.,
54 Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L. and Veilleux, R.

1 1999. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the
2 mammary gland and endometrium. *J Steroid Biochem Mol Biol* 69, 51-84.

3 Le May, C., Chu, K., Hu, M., Ortega, C.S., Simpson, E.R., Korach, K.S., Tsai, M.J. and Mauvais-
4 Jarvis, F. 2006. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-
5 deficient diabetes mellitus in mice. *Proc Natl Acad Sci U S A* 103, 9232-7.

6 Le Mellay, V., Grosse, B. and Lieberherr, M. 1997. Phospholipase C beta and Membrane Action of
7 Calcitriol and Estradiol. *J. Biol. Chem.* 272, 11902-11907.

8 Le Mellay, V., Lasmoles, F. and Lieberherr, M. 1999. Galpha(q/11) and gbetagamma proteins and
9 membrane signaling of calcitriol and estradiol. *J Cell Biochem* 75, 138-46.

10 Li, A.C., Brown, K.K., Silvestre, M.J., Willson, T.M., Palinski, W. and Glass, C.K. 2000. Peroxisome
11 proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL
12 receptor-deficient mice. *J Clin Invest* 106, 523-31.

13 Maedler, K. and Donath, M.Y. 2004. Beta-cells in type 2 diabetes: a loss of function and mass. *Horm*
14 *Res* 62 Suppl 3, 67-73.

15 Mandrup-Poulsen, T. 2003. Apoptotic signal transduction pathways in diabetes. *Biochem Pharmacol*
16 66, 1433-40.

17 Martensson, U.E.A., Salehi, S.A., Windahl, S., Gomez, M.F., Sward, K., Daszkiewicz-Nilsson, J.,
18 Wendt, A., Andersson, N., Hellstrand, P., Grande, P.-O., Owman, C., Rosen, C.J., Adamo,
19 M.L., Lundquist, I., Rorsman, P., Nilsson, B.-O., Ohlsson, C., Olde, B. and Leeb-Lundberg,
20 L.M.F. 2009. Deletion of the G Protein-Coupled Receptor 30 Impairs Glucose Tolerance,
21 Reduces Bone Growth, Increases Blood Pressure, and Eliminates Estradiol-Stimulated Insulin
22 Release in Female Mice. *Endocrinology* 150, 687-698.

23 Morley, P., Whitfield, J., Vanderhyden, B., Tsang, B. and Schwartz, J. 1992. A new, nongenomic
24 estrogen action: the rapid release of intracellular calcium. *Endocrinology* 131, 1305-1312.

25 Nadal, A., Rovira, J.M., Laribi, O., Leon-quinto, T., Andreu, E., Ripoll, C. and Soria, B. 1998. Rapid
26 insulinotropic effect of 17 β -estradiol via a plasma membrane receptor. *FASEB J.* 12, 1341-
27 1348.

28 Nakhla, A.M., Khan, M.S. and Rosner, W. 1990. Biologically active steroids activate receptor-bound
29 human sex hormone-binding globulin to cause LNCaP cells to accumulate adenosine 3',5'-
30 monophosphate. *J. Clin Endocrinol Metab.* 71, 398-404.

31 Panagiotidis, G., Salehi, A.S., Westermarck, P. and Lundquist, I. 1992. Homologous islet amyloid
32 polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. *Diabetes*
33 *Res Clin Pract* 18, 167-171.

34 Pfaffl, M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR.
35 *Nucleic Acids Res* 29, e45.

36 Prossnitz, E.R., Arterburn, J.B. and Sklar, L.A. 2007. GPR30: A G protein-coupled receptor for
37 estrogen. *Mol Cell Endocrinol* 265-266, 138-42.

38 Prossnitz, E.R., Arterburn, J.B., Smith, H.O., Oprea, T.I., Sklar, L.A. and Hathaway, H.J. 2008.
39 Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. *Annu Rev*
40 *Physiol* 70, 165-90.

41 Prossnitz, E.R. and Maggiolini, M. 2009. Mechanisms of estrogen signaling and gene expression via
42 GPR30. *Molecular and Cellular Endocrinology* 308, 32-38.

43 Prossnitz, E.R. and Maggiolini, M. 2009. Non-genomic signaling by steroids. *Molecular and Cellular*
44 *Endocrinology* 308, 1-2.

45 Prossnitz, E.R., Oprea, T.I., Sklar, L.A. and Arterburn, J.B. 2008. The ins and outs of GPR30: a
46 transmembrane estrogen receptor. *J Steroid Biochem Mol Biol* 109, 350-3.

47 Prossnitz, E.R., Sklar, L.A., Oprea, T.I. and Arterburn, J.B. 2008. GPR30: a novel therapeutic target in
48 estrogen-related disease. *Trends Pharmacol Sci* 29, 116-23.

49 Qiu, J., Rønnekleiv, O.K. and Kelly, M.J. 2008. Modulation of hypothalamic neuronal activity through
50 a novel G-protein-coupled estrogen membrane receptor. *Steroids* 73, 985-991.

51 Rae, J.M. and Johnson, M.D. 2005. What does an orphan G-protein-coupled receptor have to do with
52 estrogen? *Breast Cancer Res* 7, 243-4.

53 Ropero, A.B., Alonso-Magdalena, P., Quesada, I. and Nadal, A. 2008. The role of estrogen receptors
54 in the control of energy and glucose homeostasis. *Steroids* 73, 874-9.

- 1 Ropero, A.B., Soria, B. and Nadal, A. 2002. A Nonclassical Estrogen Membrane Receptor Triggers
2 Rapid Differential Actions in the Endocrine Pancreas. *Mol Endocrinol* 16, 497-505.
- 3 Smith, H.O., Arias-Pulido, H., Kuo, D.Y., Howard, T., Qualls, C.R., Lee, S.-J., Verschraegen, C.F.,
4 Hathaway, H.J., Joste, N.E. and Prossnitz, E.R. 2009. GPR30 predicts poor survival for
5 ovarian cancer. *Gynecologic Oncology* 114, 465-471.
- 6 Soeters, M.R., Sauerwein, H.P., Groener, J.E., Aerts, J.M., Ackermans, M.T., Glatz, J.F.C., Fliers, E.
7 and Serlie, M.J. 2007. Gender-Related Differences in the Metabolic Response to Fasting. *J*
8 *Clin Endocrinol Metab* 92, 3646-3652.
- 9 Vieira, E., Salehi, A. and Gylfe, E. 2007. Glucose inhibits glucagon secretion by a direct effect on
10 mouse pancreatic alpha cells. *Diabetologia* 50, 370-9.
- 11 Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. 2004. Global Prevalence of Diabetes. *Diabetes*
12 *Care* 27, 1047-1053.
- 13 Williams, C. and Sewing, A. 2005. G-protein coupled receptor assays: to measure affinity or efficacy
14 that is the question. *Comb Chem High Throughput Screen* 8, 285-92.
- 15 Yki-Järvinen, H. 1984. Sex and insulin sensitivity. *Metabolism* 33, 1011-1015.
- 16 Zierath, J.R., Houseknecht, K.L., Gnudi, L. and Kahn, B.B. 1997. High-fat feeding impairs insulin-
17 stimulated GLUT4 recruitment via an early insulin-signaling defect. *Diabetes* 46, 215-223.

18 19 Foot notes

20 This study was supported by the Swedish Science Council; Medical Faculty, Lund University, Novo
21 Nordic Foundation, Øresund Diabetes Academy and Albert Pålsson foundation.

22 23 Abbreviation list

24 ER, Nuclear estrogen receptor; G-1, GPR30 specific ligand, (1-[4-6-benzo [1, 3] dioxol-5-yl]-3a, 4, 5,
25 9b-tetrahydro-34-cyclopenta[c]quinoline-8-yl]-ethanone); ICI 182,780 Fulvestrant, antagonist of ER α
26 and ER β , 7-alpha-[9-(4,4,5,5-pentafluoropentylsulphonyl)nonyl]estra-1,3,5-(10)-triene-3,17-beta-
27 diol. EM-652, antagonist ER α and ER β , ((2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-
28 1-ylethoxy)phenyl]-2H-chromen-7-ol)

29 30 31 32 33 34 35 36 37 **Figure legends**

38
39 **Figure 1.** A) Relative expression of mRNA for ER α (n=6 in each group), ER β (n=6 in each group)
40 and GPR30 (n=10 in each group) analyzed by qPCR in islets from female and male mice as well as in
41 MIN6c4-cells. The expression level of GPR30 is higher in the isolated islets from female mice. In
42 MIN6c4 cells the GPR30 expression is almost negligible. B) A representative Western blot of the
43 GPR30 expression in female and male mouse islets as well as in MIN6c4 cells with an antibody
44 against GPR30. The female islets display a much stronger band than the male islets. C) The mean
45 intensity (means \pm SEM) of the Western blots (n=5 in each group) is presented as relative value of the
46 band intensity towards the endogenous control β -Actin. *p<0.05, ***p<0.001.

47
48 **Figure 2.** Confocal microscopy of female mouse islets double immunolabelled for insulin,
49 glucagon and somatostatin (green fluorescence) (A,D,G) and for GPR30, (red fluorescence) (B,E,H).
50 Co-localization of GPR30 and the different hormones is seen as orange-yellowish fluorescence(C,F,I).
51 Bar indicates length (20 μ m).

52
53 **Figure 3.** Dose-response studies of hormone secretion from female mouse islets modulated by G-1
54 and 17 β -estradiol at 1 mM glucose (A,C,E) and at 12 mM glucose (B,D,F) with the same range of
55 concentrations for both compounds as shown on the x-axis. G-1 mimics the effects of 17 β -estradiol.

1 Both compounds amplified glucose-stimulated insulin release while glucagon and somatostatin
2 secretion was reduced. The values are means \pm SEM for 8 observations in each group performed at 3
3 different occasions.

4
5 **Figure 4.** Effects of G-1 and 17 β -estradiol (E2) on islet cAMP content and insulin secretion at 12
6 mM glucose. The female islets were incubated with G-1 (100 nM) or 17 β -estradiol (100 nM or 5 μ M)
7 in the absence and presence of ICI 182,780 (100 nM) or EM-652 (100 nM). Means \pm SEM for 8
8 observations in each group are shown. ***p <0.001

9
10 **Figure 5.** A-C, Representative examples of the suppressive effect of 17 β -estradiol (E2) and G-1 on
11 cytokine-induced apoptosis (IL-1 β ; 100 ng/ml + TNF α ; 125 ng/ml + INF γ ; 125 ng/ml) from dispersed
12 female islet cells cultured for 24h, in the presence of test agents and then stained with Annexin V. A)
13 Shows an example of control tubes with and without cytokines. B-C, Shows representative examples
14 of 17 β -estradiol (5 μ M) and G-1 (100nM) effects on cytokine-induced apoptosis.

15
16 **Figure 6.** A-C, representative examples of the suppressive effect of 17 β -estradiol and G-1 on
17 cytokine-induced apoptosis (IL-1 β (100 ng/ml), TNF α (125 ng/ml), and INF γ (125 ng/ml)) from
18 dispersed female pancreatic islets cells cultured for 24h, in the presence of test agents and then stained
19 with Annexin V. A) Shows an example of cytokine-cultured tubes in the presence or absence of the
20 ER α and ER β inhibitors ICI 182,780 (100 nM) or EM-652 (100 nM). B-C) Shows representative
21 examples of the effects of 17 β -estradiol (E2) (100 nM or 5 μ M) or G-1 (100nM) together with EM-652
22 (100 nM) on cytokine-induced apoptosis..

23
24 **Figure 7.** This graph shows the collected results from n=8 observations on cytokine-induced
25 apoptosis in female islet cells performed at 5 different occasions. The data reveal that the levels of
26 apoptotic cells in cytokine-induced apoptosis (IL-1 β ; 100 ng/ml + TNF α ; 125 ng/ml + INF γ ; 125
27 ng/ml) are strongly reduced when 17 β -estradiol (E2) (100 nM or 5 μ M) or G-1 (100nM) is added in
28 presence and absence of either ICI 182,780 (100 nM) or EM-652 (100 nM) ***p <0.001.

1 **Acknowledgements**

2 The technical assistance of Britt-Marie Nilsson is gratefully acknowledged and F. Labrie is also
3 acknowledged for kindly supply of EM-652.

Figure 1

[Click here to download high resolution image](#)

Fig. 1




Fig. 2




Fig. 3





Fig. 4








Figure 6

Fig. 6






Fig. 7

